Showing results (61-70 of 89) with videos related to
Sort By:
Pageof 9
British Journal of Haematology|September 4, 2024
Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registersElin Forsgren, Sara Ekberg, Karin E Smedby, et al.Molecular Oncology|December 10, 2022
Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signaturesHaris Babačić, Silvia Galardi, Husen M Umer, et al.Breast Cancer Research and Treatment|December 1, 2017
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancerAlexios Matikas, Sara Margolin, Mats Hellström, et al.EMBO Reports|December 28, 2020
Paladin is a phosphoinositide phosphatase regulating endosomal VEGFR2 signalling and angiogenesisAnja Nitzsche, Riikka Pietilä, Dominic T Love, et al.Neuropharmacology|January 31, 2017
Inhibitory effect of punicalagin on lipopolysaccharide-induced neuroinflammation, oxidative stress and memory impairment via inhibition of nuclear factor-kappaBYoung Eun Kim, Chul Ju Hwang, Hee Pom Lee, et al.Redox Biology|January 14, 2017
Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial functionChul Ju Hwang, Young Eun Kim, Dong Ju Son, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.Cancers|May 13, 2023
Radiotherapy-Dose Escalated for Large Volume Primary Tumors-And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck-A Randomized Phase II TrialClaes Mercke, Gun Wickart-Johansson, Helena Sjödin, et al.International Journal of Cancer|September 24, 2017
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trialSiker Kimbung, Ida Markholm, Judith Bjöhle, et al.Pageof 9